Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Peninsula Research Associates

Neither a doctor nor a teaching hospital

Research payments

$1,406,314

157 payments

Through program year 2025, Peninsula Research Associates is reported as receiving $1,406,314 in research payments, across 157 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $51,835 44
2024 Research $115,606 8
2023 Research $242,028 13
2022 Research $264,473 17
2021 Research $624,278 24
2020 Research $6,558 2
2019 Research $101,535 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $759,299 30 payments
  2. Merck Sharp & Dohme Corporation $349,019 8 payments
  3. GlaxoSmithKline, LLC. $68,937 27 payments
  4. Amgen Inc. $61,997 4 payments
  5. Invivyd Inc $58,323 2 payments
  6. Novartis Pharmaceuticals Corporation $39,526 5 payments
  7. Pfizer Inc. $27,838 37 payments
  8. Shire North American Group Inc $23,042 8 payments
  9. Roche Molecular Systems, Inc. $12,809 13 payments
  10. Sanofi Pasteur Inc. $2,986 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $442,580 14 payments
  2. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $330,659 6 payments
  3. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $307,219 14 payments
  4. Canopy $58,323 2 payments
  5. A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $39,945 15 payments
  6. VOYAGER P3 AD Vaccine Study $35,050 1 payment
  7. A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma $30,936 2 payments
  8. A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian $23,492 7 payments
  9. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity $19,994 1 payment
  10. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults $18,359 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record